Bioorganic & medicinal chemistry letters · 2011
Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Thomas Mathew, Huang Wei-Sheng, Wen David, Zhu Xiaotian, Wang Yihan, Metcalf Chester A, Liu Shuangying, Chen Ingrid, Romero Jan, Zou Dong, Sundaramoorthi Raji, Li Feng, Qi Jiwei, Cai Lisi, Zhou Tianjun, Commodore Lois, Xu Qihong, Keats Jeff, Wang Frank, Wardwell Scott, Ning Yaoyu, Snodgrass Joseph T, Broudy Marc I, Russian Karin, Iuliucci John, Rivera Victor M, Sawyer Tomi K, Dalgarno David C, Clackson Tim, Shakespeare William C
Аннотация
Ponatinib (AP24534) was previously identified as a pan-BCR-ABL inhibitor that potently inhibits the T315I gatekeeper mutant, and has advanced into clinical development for the treatment of refractory or resistant CML. In this study, we explored a novel series of five and six membered monocycles as alternate hinge-binding templates to replace the 6,5-fused imidazopyridazine core of ponatinib. Like ponatinib, these monocycles are tethered to pendant toluanilides via an ethynyl linker. Several compounds in this series displayed excellent in vitro potency against both native BCR-ABL and the T315I mutant. Notably, a subset of inhibitors exhibited desirable PK and were orally active in a mouse model of T315I-driven CML.